Answers are grounded in this paper and cite their sources.
Drug-induced liver injury (DILI) is a diagnosis of exclusion that relies on a compatible temporal relationship between drug exposure and liver injury, the course after withdrawal of the suspected agent, and the exclusion of alternative etiologies. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), including semaglutide, are widely prescribed for type 2 diabetes mellitus and obesity, and semaglutide was recently approved for metabolic dysfunction-associated steatohepatitis; clinically significant hepatotoxicity has been reported only rarely. We describe a 56-year-old woman with obesity, without diabetes, who presented to the emergency department with right flank pain 89 days after starting oral semaglutide 3 mg once daily. Aspartate aminotransferase and alanine aminotransferase levels were 14.6 and 10.2 times the upper limit of normal, respectively, with elevated gamma-glutamyl transferase (GGT), mild hyperbilirubinemia, and a normal alkaline phosphatase level (R ratio 11.1, hepatocellular pattern). Serology for hepatitis A, B, C, and E and antinuclear antibodies were negative, creatine kinase was normal, and unenhanced abdominopelvic CT showed no significant biliary dilatation, choledocholithiasis, or features of acute cholecystitis. Semaglutide was discontinued, whereas fluoxetine and clonazepam, started approximately six months earlier, and olmesartan were continued. Liver tests improved progressively, with a 54% reduction in the elevation of alanine aminotransferase above the upper limit of normal (ULN) by day 7. The updated Roussel Uclaf Causality Assessment Method (RUCAM) score was 6 (probable) for semaglutide, 4 (possible) for fluoxetine, and 2 (unlikely) for both clonazepam and olmesartan, and the injury was graded as mild. Transient biliary obstruction could not be completely excluded, as the abdominal ultrasound result and laboratory follow-up beyond day 7 were not available. This case suggests that semaglutide should be considered in the differential diagnosis of unexplained hepatocellular liver injury and highlights the need for a structured causality assessment that includes the exclusion of biliary disease, a recognized complication of this drug class.
No takes yet. Share an insight, caveat, or question.
Freitas et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: